AI Article Synopsis
- The study aimed to evaluate the SCC antigen levels in benign diseases to identify potential false positives in epidermoid carcinoma assessments.
- Serum tests using the Abbott SCC-RIA kit were conducted on 1,412 individuals, including healthy controls and women with benign diseases.
- Results indicated that a significant percentage of patients with chronic conditions showed SCC antigen values above the normal threshold, suggesting that this marker may not be reliable in these populations, increasing the risk of misleading positive results.
Article Abstract
Background: The values of the squamous cell carcinoma (SCC) antigen in benign diseases were studied with the aim of determining false positive values in the study of epidermoid carcinomas.
Methods: Serum determinations of the SCC antigen were performed by radioimmunoanalysis with the Abbott SCC-RIA kit. The control group was made up of a total of 719 subjects of whom 317 were healthy blood donors and 402 were healthy women with normal cervicovaginal cytology. The study group was made up of 693 women with benign diseases.
Results: Ninety-eight point two percent of the subjects from the control group presented values under 2.5 ng/ml, therefore this value was chosen as the maximum limit of normality. Higher values than this threshold of normality were observed in 11.7% of the 34 patients with chronic disease (0.1-18.2 ng/ml) and in 57.5% of the 40 patients with chronic renal failure (0.5-6.0 ng/ml).
Conclusions: In patients with chronic liver disease or chronic renal failure, the serum determination of the squamous cell carcinoma antigen loses its value as a tumor marker of epidermoid carcinomas given the risk of obtaining false positive values.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Surgical treatment of keratinocyte carcinoma in Danish hospitals 2007-2021: Time trends and impact of patient and tumor characteristics on treatment choices.
J Plast Reconstr Aesthet Surg
January 2025
Department of Plastic Surgery, Odense University Hospital, Denmark.
The incidence of keratinocyte carcinoma (KC) is rising globally, significantly burdening healthcare resources. Treatment options include medical treatment, non-invasive procedures, and surgery, each associated with their distinct benefits and risks. With advanced treatment, the procedures become increasingly invasive for the patients and expensive for the society.
View Article and Find Full Text PDFSurgical Outcomes for Nonmelanoma Skin Cancer of the Head and Neck.
Ann Plast Surg
January 2025
Department of Plastic Surgery, First Affiliated Hospital of Kunming Medical University, Kunming City, Yunnan Province, China.
Objectives: There is no consensus on elective lymphatic dissection of the parotid and neck for nonmelanoma skin cancer (NMSC) due to challenges in detecting occult spread to these regions. This study aimed to summarize clinical data and evaluate correlations between risk factors, nodular metastasis, and the need for elective parotidectomy in patients with cutaneous squamous cell carcinoma (CSCC), Merkel cell carcinoma (MCC), and apocrine carcinoma (AC) of the head and neck, all with clear surgical margins and negative imaging results for regional metastases.
Study Design: We retrospectively reviewed 166 patients with CSCC, one with MCC, and one with AC of the head and neck, all treated surgically between September 2006 and July 2022.
Outcomes of 100 Squamous Cell Carcinomas of the Upper Limb: 100 Squamous Cell Carcinomas of the Upper Limb.
Ann Plast Surg
January 2025
From the Birmingham Hand Centre, University Hospital Birmingham, Birmingham, AL.
Background: Rates of recurrence, metastases, and mortality for squamous cell carcinoma (SCC) of the upper limb have not been clearly defined.
Objective: We aimed to characterize these tumors and assess the long-term outcomes, comparing with current literature.
Methods And Materials: A retrospective review was performed on 100 consecutive primary cutaneous upper limb SCCs managed surgically by a single hand surgeon between 2012 and 2019.
Lineage tracing studies suggest that the placenta is not a de novo source of hematopoietic stem cells.
PLoS Biol
January 2025
Cardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Definitive hematopoietic stem and progenitor cells (HSPCs) arise from a small number of hemogenic endothelial cells (HECs) within the developing embryo. Understanding the origin and ontogeny of HSPCs is of considerable interest and potential therapeutic value. It has been proposed that the murine placenta contains HECs that differentiate into HSPCs.
View Article and Find Full Text PDFCharacterizing temporal and global host innate immune responses against SARS-CoV-1 and -2 infection in pathologically relevant human lung epithelial cells.
PLoS One
January 2025
Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and -2 (SARS-CoV-2) are beta-coronaviruses (β-CoVs) that have caused significant morbidity and mortality worldwide. Therefore, a better understanding of host responses to β-CoVs would provide insights into the pathogenesis of these viruses to identify potential targets for medical countermeasures. In this study, our objective is to use a systems biology approach to explore the magnitude and scope of innate immune responses triggered by SARS-CoV-1 and -2 infection over time in pathologically relevant human lung epithelial cells (Calu-3/2B4 cells).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!